Real-world experience of sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for FLT3-ITD AML reveals high rates of toxicity-related treatment interruption

Sorafenib significantly improves survival of FLT3-ITD mutated AML patients when used as a post-allogeneic HSCT maintenance. Importantly, clinical trials reported a low rate of toxicities requiring sorafenib discontinuation. The aim of our analysis was to evaluate the real-world experience in patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Morin, Sarah, Giannotti, Federica, Mamez, Anne-Claire, Pradier, Amandine, Masouridi-Levrat, Stavroula, Simonetta, Federico, Chalandon, Yves
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10050716/
https://www.ncbi.nlm.nih.gov/pubmed/37007116
http://dx.doi.org/10.3389/fonc.2023.1095870

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10050716/
https://www.ncbi.nlm.nih.gov/pubmed/37007116
http://dx.doi.org/10.3389/fonc.2023.1095870

Ejemplares similares